DR info

Clinical trials : 6 / Drugs : 2 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathways : 51

Lymphangiomatosis and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability

ID	Diseases (Sorted by drug repositionability)
277	Lymphangiomatosis
278	Huge lymphatic malformation with cervicofacial lesion
279	Huge venous malformation with cervical, oral and pharyngeal diffuse lesion
280	Huge arteriovenous malformation with cervicofacial or limb lesion
281	Klippel-Trenaunay-Weber syndrome
283	Acquired pure red cell aplasia
285	Fanconi anemia
331	Idiopathic multicentric castleman disease
228	Bronchiolitis obliterans
36	Epidermolysis bullosa
13	Multiple sclerosis/Neuromyelitis optica
193	Prader-Willi syndrome
6	Parkinson disease
2	Amyotrophic lateral sclerosis
62	Paroxysmal nocturnal hemoglobinuria
63	Idiopathic thrombocytopenic purpura
15	Inclusion body myositis
17	Multiple system atrophy
19	Lysosomal storage disease
34	Neurofibromatosis
35	Pemphigus
46	Malignant rheumatoid arthritis
49	Systemic lupus erythematosus
51	Scleroderma
60	Aplastic anemia
61	Autoimmune hemolytic anemia
65	Primary immunodeficiency
66	IgA nephropathy
67	Polycystic kidney disease
84	Sarcoidosis
85	Idiopathic interstitial pneumonia
86	Pulmonary arterial hypertension
89	Lymphangioleiomyomatosis
96	Crohn disease
98	Eosinophilic gastrointestinal disease
127	Frontotemporal lobar degeneration
137	Focal cortical dysplasia
157	Sturge-Weber syndrome
158	Tuberous sclerosis
192	Cockayne syndrome
222	Primary nephrotic syndrome
256	Muscle glycogenosis